Status:
UNKNOWN
Exhaled Carbon Monoxide and Red Blood Cell Turnover
Lead Sponsor:
University of Cincinnati
Collaborating Sponsors:
VA Office of Research and Development
Conditions:
Diabetes Mellitus
Healthy
Eligibility:
All Genders
18-75 years
Brief Summary
Hemoglobin A1C (HbA1c) is the cornerstone of blood sugar monitoring. As HbA1c is formed by the covalent reaction of glucose with hemoglobin throughout the lifespan of the red blood cell (RBC), it is u...
Detailed Description
Recently Investigators have demonstrated that RBC lifespan has substantial inter-individual variation even in people without diabetes or obvious hematologic diseases affecting RBC lifespan (5,6). Inve...
Eligibility Criteria
Inclusion
- Subjects will be between age 18 and 75 years, non-pregnant, with a goal of equal gender and race (Caucasian vs. African-American) distribution
Exclusion
- known hemoglobinopathy or RBC disorder
- positive pregnancy test (in women of child-bearing potential or are breast feeding or planning pregnancy during the course of the study;
- baseline serum creatinine \>1.5 mg/dl
- CBC outside the normal range
- history of GI blood loss or coagulopathy
- urine microalbumin \>100 mcg/mg creatinine (spot collection);
- transaminases \>3 X the upper limit of normal
- presence of serum antibodies to biotinylated proteins (which could interfere with the biotin RBC labeling protocol)
- greater than or equal to NYHA stage 3 heart failure;
- active infection;
- known rheumatologic disease
- uncontrolled hypo-or hyperthyroidism or an underlying illness known to be associated with either body wasting or changes in serum proteins
- lung transplantation, irradiation, recent surgery, recent intensive care admission, asthma, COPD, cystic fibrosis, smoking, recent hematoma, uncontrolled hypo- or hyperthyroidism or an underlying illness known to be associated with either body wasting or changes in serum proteins (e.g. certain malignancies including multiple myeloma or tuberculosis).
Key Trial Info
Start Date :
April 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03288233
Start Date
April 1 2015
End Date
August 1 2018
Last Update
September 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cincinnati
Cincinnati, Ohio, United States, 45220